ENABLING THE NEXT ERA OF INFORMED CANCER CARE.

alt text for all sources

THE 2024 ASCO® ANNUAL MEETING

BOOTH #29065 | CHICAGO, ILLINOIS | MAY 31-June 4

Discover how Exact Sciences is redefining cancer care, from risk to screening to treatment insights.

From the maker of the Oncotype DX Breast Recurrence Score® test, a trusted tool to help inform treatment decisions in early-stage breast cancer patients, comes a comprehensive portfolio of screening and genomic tests.

Detect signs of colorectal cancer earlier with the Cologuard® test, gain valuable insights into hereditary cancer risk using the Riskguard test, or pinpoint actionable genomic variants in advanced-stage solid tumors with the OncoExTra® test. Explore our booth to learn about our upcoming innovations, such as the Oncodetect test designed to detect molecular residual disease (MRD) in solid tumors, and the Cancerguard test, which aims to identify multiple cancers in their earliest stages from a single blood draw.1

Reference: 1. Ahlquist DA. Universal cancer screening: revolutionary, rational, and realizable. NPJ Precis Oncol. 2018;2:23.

Treatment Insights

Early Detection

Innovation

Treatment insights

Make pivotal cancer treatment decisions with timely, actionable insights. Our diverse portfolio of genomic and genetic tests provides personalized guidance at key moments, spanning from risk assessment and recurrence monitoring to therapy selection for advanced-stage cancer.

PREDICTING CHEMOTHERAPY BENEFIT IN EARLY-STAGE HR+, HER2- BREAST CANCER

Oncotype Dx logo

The Oncotype DX Breast Recurrence Score® test is the only genomic test proven to predict a patient’s individual benefit from chemotherapy.1,2

HEREDITARY CANCER RISK ASSESSMENT

Riskguard logo

The RiskguardTM test is a 56-gene risk assessment tool that identifies hereditary genetic changes that may impact clinical decision-making in breast, ovarian, prostate, endometrial, colorectal, pancreatic, gastric, kidney, endocrine, and skin cancers. Not available in all countries.

Incorporating the Riskguard test alongside the Oncotype DX Breast Recurrence Score test for patients with early-stage cancer enhances the depth of insight into their cancer’s behavior and broadens treatment options based on genetic factors.

The Riskguard test, in conjunction with the OncoExTra® test, offers a comprehensive approach for patients with advanced cancer. This combined testing delivers thorough information covering both inherited (germline) and tumor (somatic) characteristics, in accordance with established guidelines.

ADVANCED CANCER TREATMENT SELECTION

 

The OncoExTra test is an ultra-comprehensive genomic test that uses DNA and RNA to identify clinically actionable alterations and any associated therapies or clinical trials—delivering your patient’s complete genomic story in one streamlined report. Not available in all countries.


References: 
1. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006;24(23):3726-3734.
2. Albain KS, Barlow WE, Shak S, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 2010;11(1):55-65.

Early detection

The first step in changing the way we treat cancer? Detecting it earlier. Our screening tests can deliver earlier answers to help drive care decisions. Not available outside the United States.

THE USE AT-HOME STOOL DNA TEST

Cologuard logo

A noninvasive, FDA-approved colorectal cancer screening test that looks for multiple abnormal biomarkers, including DNA and blood in stool, the Cologuard® (multi-target stool DNA [mt-sDNA]) test finds colon cancer even in early stages when it is more treatable.1-3* Not available outside the United States. For adults 45+ at average risk. Rx only.

EARLY-STAGE LIVER CANCER DETECTION

Oncoguard® Liver logo.

A sophisticated, yet simple, single blood test, the Oncoguard® Liver solution delivers advanced sensitivity and specificity to aid consistent and reliable hepatocellular cancer detection. Not available outside the United States.


*Based on 5-year relative survival.


References: 
1. Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med. 2014;370(14):1287-1297.
2. Cologuard Clinician Brochure. Exact Sciences Corporation. Madison, WI.
3. American Cancer Society. Survival rates for colorectal cancer. Accessed April 4, 2024. https://www.cancer.org/cancer/colon-rectal-cancer/detection-diagnosis-staging/survival-rates.html

 

 

Innovation

The future depends on today’s accomplishments. Our team of innovators is constantly working to develop life-changing solutions in cancer screening and genomic tests.

COLORECTAL CANCER SCREENING

The Next-Generation mt-sDNA Test

Building on the success of the Cologuard® test, the development of the next-generation multi-target stool DNA (mt-sDNA) test aims to preserve the convenience of a use-at-home stool DNA test while enhancing test performance, with the goal of improving the patient experience.

Colorectal Cancer Blood Test

To provide more options for the approximately 60 million average-risk Americans aged 45 to 85 years who remain unscreened, Exact Sciences is developing a blood-based screening method for colorectal cancer to give you and your patients more choices.1

MULTI-CANCER EARLY DETECTION

Cancerguard™ Logo.

Only one-third of diagnosed cancers have routine recommended screening tests.2* Many more cancers may go undetected until they are more advanced.3 The Cancerguard test in development is being designed to detect multiple cancers, even in their earliest stages, from a single blood draw.3 When used alongside single-organ standard-of-care cancer screenings, such as breast and colorectal cancer screenings, multi-cancer early detection (MCED) tests may offer the potential to transform the way we screen for cancer.

Join us for an MCED Industry Expert Theater on June 2nd. Full event details below.

MOLECULAR RESIDUAL DISEASE (MRD)

oncodetect Logo

We’re developing the Oncodetect test to find circulating tumor DNA before, during, and after cancer treatment. Results have the potential to provide insights for earlier detection of recurrence and inform treatment decisions.


The technologies in this section are under development. The features described are current development goals. They have not been cleared or approved by the US Food and Drug Administration or any other national regulatory authority.

References: 
1. Ebner DW, Kisiel JB, Fendrick AM, et al. Estimated average-risk colorectal cancer screening-eligible population in the US. JAMA Netw Open. 2024;7(3):e245537.
2. Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12-49.
3. Ahlquist DA. Universal cancer screening: revolutionary, rational, and realizable. NPJ Precis Oncol. 2018;2:23.

*Calculated using estimated new diagnoses and deaths from cancers that have standard-of-care screening: breast, cervical, colorectal, and lung (high-risk) against all sites.

ATTEND OUR JUNE
2nd INDUSTRY EXPERT THEATER

PIONEERING A PARADIGM SHIFT IN CANCER SCREENING:

The Era of Multi-Cancer Early Detection Testing

Single-organ cancer screening won’t be enough to stop cancer from becoming the #1 anticipated cause of death by year 2030.1 MCED tests show promise in early cancer detection. Learn how a rigorous approach to MCED test development may lead to a paradigm shift that helps reduce the burden of cancer.

Not an official event of the 2024 ASCO® Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, or Conquer Cancer®, the ASCO Foundation. Not CME-accredited.

 

Tomasz M. Beer, MD, FACP

Chief Medical Officer and VP, Multi-Cancer Early Detection, Exact Sciences


Frank Diehl, PhD

SVP Research and Development, Multi-Cancer Early Detection, Exact Sciences

 

Sunday, June 2 | 9:45 AM – 10:45 AM
Exhibit Hall, Industry Expert Theater 1

Abstracts of interest

Recurrence Score® gene axes scores and outcomes by race and ethnicity in the RxPONDER trial

Authors

Yara Abdou, Jess Hoag, William Barlow, Julie Gralow, Funda Meric-Bernstam, Kathy Albain, Daniel Hayes, Nancy Lin, Edith Perez, Lori Goldstein, Stephen Chia, Sukhbinder Dhesy-Thind, Priya Rastogi, Anne Schott, Jennifer Racz, Debashish Tripathy, Gabriel Hortobagyi, Lajos Pusztai, Priyanka Sharma, Kevin Kalinsky

Abstract Number

515

Updated SEER database study of 21-gene assay to assess breast cancer–specific mortality and benefit of chemotherapy by race and ethnicity

Authors

Emilia Diego, John Bennett, Gong Tang, Charles Geyer, Jennifer Racz, Christy Russell, Frederick Baehner, Steven Shak, Valentina Petkov

Abstract Number

533

Effect of multi-cancer early detection screening on late-stage cancers: a modeling study

Authors

Jagpreet Chhatwal, Jade Xiao, Selin Merdan, Andrew ElHabr, Christopher Tyson, Xiting Cao, Sana Raoof, A. Mark Fendrick, Burak Ozbay, Paul Limburg, Tomasz M. Beer, Ashish Deshmukh, Andrew Briggs

Abstract Number

11076

Advocacy
reception

Sunday, June 2th
7:00pm - 9:00pm
Palmer House Hilton
This is an invite-only event

EXACT SCIENCES’ ADVOCACY RECEPTION

 

Exact Sciences is proud to host representatives from prominent US patient advocacy organizations for an enlightening evening of fellowship, including a dynamic discussion on increasing equitable access to biomarker testing. Invitees will learn about the latest advancements in our test portfolio, designed to support individuals at every stage of their cancer experience. Everyone will walk away with an understanding of our commitment to revolutionizing cancer care—before, during, and after diagnosis.

PRESS RELEASE


Tests may not be commercially available outside the United States.